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Opioid agonistic and antagonistic peptides which are inactive within the sequence of the
precursor milk proteins can be released and thus activated by enzymatic proteolysis, for example
during gastrointestinal digestion or during food processing. Activated opioid peptides are
potential modulators of various regulatory processes in the body. Opioid peptides can interact
with subepithelial opioid receptors or specific luminal binding sites in the intestinal tract.
Furthermore, they may be absorbed and then reach endogenous opioid receptors.
Opioid peptides: Milk protein
Introduction
Milk proteins are potential sources of opioid agonistic and
antagonistic peptides. The structures of biologically active
sequences were obtained from in vitro enzymatic and/or by
in vivo gastrointestinal digests of the appropriate precursor
proteins; chemical synthesis has been carried out to confirm
the sequence of potential bioactive peptides (for reviews,
see Teschemacher et al. 1990, 1994, 1997; Meisel, 1997a).
General structural features
Opioid peptides, i.e. opioid receptor ligands with agonistic
activity, originate from different milk proteins and exert
naloxone-inhibitable opioid activities in both receptor
studies and during bioassays (Brantl et al. 1981). Milk-
protein derived opioid peptides have been designated as
`atypical' opioid peptides (Teschemacher et al. 1994).
These opioid peptides have N-terminal sequences different
from that of the `typical' endogenous opioid peptides, e.g.
enkephalins, endorphins and dynorphins. `Typical' opioid
peptides are derived from three precursor molecules,
proenkephalin, prodynorphin and proopiomelanocortin
(HoÈllt, 1983). The common structural feature among
endogenous and exogenous opioid peptides is the presence
of a tyrosine residue at the amino terminal end (except a-
casein opioids) and the presence of another aromatic
residue, e.g. phenylalanine or tyrosine, in the third or fourth
position (Table 1). This is an important structural motif
which fits into the binding site of opioid receptors. The
negative potential, localized in the vicinity of the phenolic
hydroxyl group of tyrosine, seems to be essential for opioid
activity. Removal of the tyrosine residue results in a total
absence of bioactivity (Chang et al. 1981). The proline
residue in the second position (Pro2) is crucial for the
biological activity of opioid peptides because it is reported
to maintain the proper orientation of the Tyr and Phe side
chains (Mierke et al. 1990).
Opioid antagonists are peptides related to `atypical'
opioid peptides, i.e. they are opioid receptor ligands sharing
several characteristics with agonistic opioid peptides
derived from milk proteins (Teschemacher et al. 1994).
They are not found in the sequence of endogenous
precursors and their N-terminal amino acid sequence is
not identical with that of the `typical' opioid peptides.
Occurrence in the sequence of milk proteins
The major exogenous opioid peptides, i.e. b-casomorphins,
are fragments of the b-casein sequence 60±70 (Tyr-Pro-
Phe-Pro-Gly-Pro-Ile-Pro-Asn-Ser-Leu) (Table 1) and have
been characterized as m-type ligands (Teschemacher et al.
1994, 1997). b-Casomorphins were found in analogous
positions in sheep, water buffalo and human b-casein (for
review, see Fiat & JolleÁs, 1989; Teschemacher et al. 1990;
Meisel & Schlimme, 1996; Meisel, 1997a,b). An analogue
isolated from a commercial hydrolysate of bovine casein,
b-casomorphin-4-amide, designated as morphiceptin, is a
highly potent m-selective opioid peptide (Chang et al.
1981). Three a-casein-derived exorphins corresponding to
bovine aS1-casein peptide fragments 90±96 (Arg-Tyr-Leu-
Gly-Tyr-Leu-Glu), 90±95 and 91±96 are d-selective
receptor ligands (Loukas et al. 1983, 1990; Pihlanto-
LeppaÈlaÈ et al. 1994). Whey protein-derived peptides which
behave as m-opioid receptor agonists with low potency are
the a-lactorphin (Tyr-Gly-Leu-Phe) and b-lactorphin (Tyr-
Leu-Leu-Phe) corresponding to residues 50±53 in both
bovine and human a-lactalbumin and 102±105 in bovine
b-lactoglobulin, respectively (Chiba & Yoshikawa, 1986;
Antila et al. 1991). Another whey protein-derived opioid
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peptide, serorphin (Tyr-Gly-Phe-Asn-Ala), was isolated
from fragment 399±404 of serum albumin (Tani et al.
1994).
Opioid antagonists have been found in bovine and
human k-casein (casoxins) and in aS1-casein (Chiba et al.
1989; Yoshikawa et al. 1994). Various synthetic casoxins
were isolated as C-terminally methoxylated peptides, e.g.
the derivatives corresponding to k-casein sequences 33±38
(Ser-Arg-Tyr-Pro-Ser-Tyr OCH3), 34±38 and 35±38
(Chiba & Yoshikawa, 1986). The chemically modified
casoxins were more active than the non-methoxylated
fragments. The tryptic fragment corresponding to residues
25±34 (Tyr-Ile-Pro-Ile-Gln-Tyr-Val-Leu-Ser-Arg) of
bovine k-casein, known as casoxin C, showed a relatively
high opioid antagonistic activity in comparison to the
esterified peptides (Chiba et al. 1989). Casoxins are opioid
receptor ligands of the m-type with relatively low
antagonistic potency as compared with naloxone. They
also bind to k-receptors where extension of the N-terminal
amino acid sequence beyond the tyrosine residue seems to
influence binding to k-type receptors. Opioid antagonists
were also found in human lactoferrin (Yoshikawa et al.
1988). These peptides, named lactoferricin A (fragment
339±344), B (fragment 544±548) and C (fragment 681±
687), behaved quite similarly to casoxins, i.e. C-terminally
methoxylated m-opioid receptor-selective antagonists with
moderate potency (Teschemacher et al. 1997).
Functional significance
Mammalian opioidergic systems consist of opioid receptors
and their endogenous ligands, the opioid peptides. Depend-
ing on their location, their physiological significance
appears to be related to a considerable number of
neuroendocrine regulatory functions. Opioid receptors (m-,
d- and k-type) are located in the nervous, endocrine and
immune systems as well as in the intestinal tract of the
mammalian organism and can interact with their endogen-
ous ligands as well as with exogenous opioids and opioid
antagonists (Teschemacher et al. 1994). Thus, opioidergic
systems are open to all kinds of interferences from
exogeneous opioids or opioid antagonists (Teschemacher
et al. 1994). Modulation of social behaviour (Panksepp
et al. 1984; Paroli, 1988) and analgesic effects (Chang et al.
1982; Matthies et al. 1984) were observed following
intracerebral administration of opioid peptides with
agonistic activity, e.g. b-casomorphins, to experimental
animals. Orally administered milk protein-derived opioid
peptides have been demonstrated to influence postprandial
metabolism by stimulating secretion of insulin and
somatostatin (Schusdziarra et al. 1983a,b), to modulate
intestinal transport of amino acids (Brandsch et al. 1994),
to prolong gastrointestinal transit time and to exert
antidiarrhoeal action (Daniel et al. 1990a,b). Evidence
has accumulated that the enhancement of net water and
electrolyte absorption by b-casomorphins in the small and
large intestine is a major component of their antidiarrhoeal
action, which could be mediated via subepithelial opioid
receptors or through specific luminal binding sites at the
brush border membrane (TomeÂ et al. 1987; Brandsch et al.
1994). b-Casomorphins may also affect the human
mucosal immune system, possibly via opiate receptors in
lamina propria lymphocytes (Elitsur & Luk, 1991).
The presence of opioid peptides in a living system or, at
least, of the precursors from which these peptides could be
liberated, is a prerequisite for any functional role in the
system. It can be shown that relatively high amounts of
bioactive peptides could potentially be produced during the
ingestion of 1 g of each of the major casein and whey
protein components (Table 1). Many opioid peptides are
biologically very potent. Therefore, even nutritionally
insignificant amounts of liberated peptides might be
sufficient to exert physiological effects. These peptides
may enter peripheral blood intact and exert systemic effects
or they may produce local effects in the gastrointestinal
tract. Results indicating the liberation of b-casomorphins
from b-casein under in vivo conditions have been obtained
from several studies. Evidence for the liberation of b-
casomorphins from b-casein into the gastrointestinal lumen
of mammals after milk intake has also been obtained.
Peptides were found in the small intestinal contents of adult
humans following cows' milk intake, which were identified
by radioimmunological and chromatographical methods as
b-casomorphins (Svedberg et al. 1985). Moreover, b-
casomorphin-11 has been identified and chemically char-
acterized in the duodenal chyme of GoÈttingen minipigs
after feeding with bovine casein (Meisel, 1986). b-
Casomorphins are claimed to be rapidly degraded once
Table 1. Examples of opioid peptides derived from bovine milk proteins (adapted from Meisel & Bockelmann, 1999 and Antila et al. 1991)
Bioactive peptide Sequence*
Precursor protein
(fragment)
IC50
²
(mmol/l)
Theoretical yield of
bioactive peptide obtainable
from 1 g precursor protein (mg)
Opioid agonists
b-Casomorphin-7 YPFPGPI b-Casein (f60±66) 14.0 33.0
b-Casomorphin-5 YPFPG b-Casein (f60±64) 1.1 24.2
as1-Casein-exorphin RYLGYLE as1-Casein (f90±96) 1.2 38.7
a-Lactorphin YGLF a-Lactalbumin (f50±53) 67.0 35.2
b-Lactorphin YLLF b-Lactoglobulin (f102±105) 38.0 30.2
Serorphin YGFNA Serum albumin (f399±404) 85.0 10.5
Opioid antagonists
Casoxin A YPSYGLNY k-Casein (f35±42) 400.0 51.4
Casoxin B YPYY k-Casein (f58±61) 31.8
Casoxin C YIPIQYVLSR k-Casein (f25±34) 50.0 65.8
* The one-letter amino acid code is used.
² Peptide concentration required to inhibit 3H-ligand binding by 50 %.
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they enter the bloodstream. However, the presence of b-
casomorphin-7 immunoreactive material has been demon-
strated in the plasma of newborn calves following their first
milk intake (Umbach et al. 1985). This material revealed a
similar molar mass as b-casomorphin-11 and thus has been
considered as a b-casomorphin precursor. Such pre-
casomorphins could reach any potential site of action in
the system to elicit physiological effects following libera-
tion of the protected active sequence from the precursor
molecule. Opioid casein fragments have not been detected
in the plasma of adult mammals (Umbach et al. 1985;
Teschemacher et al. 1986). Thus, only the neonatal
intestine appears to be permeable to (pre-)casomorphins;
in adult systems, the intestinal brush border membrane
seems to be the main target site for the physiological effects
of food-derived opioid peptides.
In addition to the possible liberation of bioactive
peptides during intestinal proteolysis, such peptides may
already be generated during manufacture of several milk
products and thus be ingested as food components. For
example, partially hydrolysed milk proteins for hypoaller-
genic infant formulas and for clinical applications in enteral
nutrition consist exclusively of peptides. Furthermore, it
has been demonstrated that a number of caseolytic bacterial
species used in the production of some types of cheese and
other milk products can produce casomorphins (Hamel et al.
1985). Several opioid peptides derived from aS1-, b-casein
and a-lactalbumin were released by pepsin/trypsin hydro-
lysis of Lactobacillus GG fermented UHT milk (Rokka
et al. 1997). It has been found that the extracellular PI-type
proteinase of Lactococcus lactis hydrolyses more than 40
% of the peptide bonds of b-casein resulting in the
formation of more than 100 different oligopeptides
including a fragment of the b-casein sequence 60±68
which is part of b-casomorphin-11 (Juillard et al. 1995).
Data obtained from `non-starter' lactic acid bacteria
(Lactobacillus ssp.) present in fermented milk products
and in the human intestine indicate that their proteolytic
system is comparable to Lactococcus lactis. No data are
available on the action of the proteolytic enzymes from
lactic acid bacteria in the human gut after ingestion of
fermented milk products.
Irrespective of the potential function of milk-derived
opioids as exogenous regulators, it is also possible that
certain peptides from milk may directly influence the
mother. For example, casomorphins can be liberated in the
mammary gland, transferred to the blood and then reach
endogenous opioid receptors (Teschemacher & Koch,
1990). In this way, casomorphins may participate in the
endocrinic regulation of pregnancy, e.g. by stimulation of
prolactin release (Yen et al. 1985). The cardiovascular
system in pregnant or lactating mammals may also be a
target for casomorphin action. These peptides can exert a
positive inotropic and antiarrhythmic effect and thus may
have a cardioprotective function (Mentz et al. 1990;
Teschemacher & Koch, 1990). The physiological signifi-
cance of these effects is as yet not clear.
Dietary and pharmaceutical applications
b-Casomorphins have been produced by genetic engineering
techniques followed by enzymatic or chemical cleavage of
the microbial fusion protein to liberate the required peptide
(Carnie et al. 1989). These recombinant b-casomorphins
are intended for oral administration in order to increase
animal performance, e.g. weight gain or milk yield. As yet,
no meaningful application in human nutrition has been
described.
Several attempts were made to synthesize modified b-
casomorphin sequences in order to find pharmacologically
active peptides with higher analgesic potency, altered side-
effects and longer duration of action. A considerable
increase in analgesic or antidiarrhoeal activity in dogs was
obtained by substitution of L- with D-amino acids, e.g. Pro2
and Pro4, and by C-terminal amidation (Matthies et al.
1984; Daniel et al. 1990b; Mansfeld et al. 1990; Erll et al.
1994). Examples of chemically modified potent opioid
peptides include morphiceptin (b-casomorphin-4-amide)
and casokefamide (D-Ala2,4,Tyr5-b-casomorphin-5-amide).
Modifications to the natural casomorphins do not only
influence the affinity of the resulting analogues for opioid
receptors, but also alter their pharmacokinetics, particularly
their inactivation by proteolytic/peptideolytic enzymes:
substituted b-casomorphins have been shown to be more
resistant to enzymatic attack and exhibit higher opioid
potency than the natural peptides (TomeÂ et al. 1987; Daniel
et al. 1990b).
Conclusions
The bioactivities of opioid peptides encrypted in major
milk proteins are latent until released and activated by
enzymatic proteolysis, e.g. during gastrointestinal digestion
or food processing. It is evident from many studies that
opioid peptide fragments originating from milk proteins are
potential regulatory compounds and modulators of various
regulatory processes in the body. Nevertheless, more
research is needed to fully understand the physiological
significance of milk-protein derived opioid peptides. b-
Casomorphins and chemically modified analogues have
already been considered for interesting applications as
supplements for animal feed and as pharmaceutical
preparations.
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